

**SCRIPPS RESEARCH
INSTITUTIONAL BIOSAFETY COMMITTEE
MEETING MINUTES
June 11, 2025**

I. MEETING

The Institutional Biosafety Committee (IBC) of Scripps Research held a meeting via videoconference on June 11, 2025, commencing at 2 p.m. Pacific Time. The meeting was held pursuant to notice duly given and a quorum was present.

Committee Members Present		Committee Members Absent	Others Present
Juan Carlos de la Torre	Michael Bobardt	Jim Gohres	Amy Green
Stephen Munday	Smita Chopade	Raphael Park	
Elizabeth Ford	Cheryl Andreoli	Steven Robert Head	
Roberto Aiolfi	Elizabeth Montano		
Mychelle Fernandez	Case McNamara		
Elyse Walk			

I. REVIEW OF PREVIOUS MEETING MINUTES

The Committee voted unanimously to approve the minutes of the May 16, 2025 IBC Meeting.

II. ANNOUNCEMENTS

None.

III. BIOSAFETY OFFICER & IBC ADMINISTRATOR'S REPORT

As a procedural update, IBC protocols will be reviewed as they come in and conditionally approved until training is complete.

IV. CONFLICT OF INTEREST

Case McNamara will abstain from voting on his protocol #09-26-18-05.

V. REVIEW OF PROTOCOLS

FULL COMMITTEE REVIEW

MIGRATIONS

1. IBC Protocol #: 09-26-18-05, McNamara, Case
Title of Study: Drug discovery for bacterial infections
Department: Biology- Calibr
Primary Reviewer: Mychelle Fernandez
Secondary Reviewer: Roberto Aiolfi
NIH Guidelines: III-D-1
Biosafety Level: BSL-2+
Animal work: ☐ Yes ☒ No
Biosafety Inspection: Inspection of Calibr 124, 121E, IDR 213 completed 9/5/2023.
Training: Training verified and on record.

Summary of Discussion: **Summary of Discussion:** A summary of the research proposal was thoroughly discussed, including but not limited to: agent characteristics; types of manipulations planned; sources of the nucleic sequences; nature of the nucleic acid sequences; hosts and vectors to be used; whether any attempt will be made to obtain expression of a transgene, and if so, the function of the protein that will be produced. The committee assessed key risks presented by the research and confirmed the appropriate biocontainment level for the conduct proposed.

The following action items were identified as needing to be updated on the protocol:

Location of Study

Room 224 needs to be added, this is where plates are read.

Exposure Control

If Materials will be transferred off campus, DOT hazardous material shipping training must be selected and completed.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

2. IBC Protocol #: 11-08-17-02, Lipton, Stuart

Title of Study: Stereotaxic Transcranial Injection of Lentiviral Constructs and Live Cells into the Mouse Brain

Department: Molecular & Cellular Biology

Primary Reviewer: Beth Ford

Secondary Reviewer: Cheryl Andreoli

NIH Guidelines: III-D-1, III-D-4

Biosafety Level: BSL-2+, ABSL-2

Animal work: ☒ Yes ☐ No

Biosafety Inspection: Inspection of CHWL 162, 38, 37 to be completed 7/2/2025.

Training: Training verified and on record.

Summary of Discussion: A summary of the research proposal was thoroughly discussed, including but not limited to: agent characteristics; types of manipulations planned; sources of the nucleic sequences; nature of the nucleic acid sequences; hosts and vectors to be used; whether any attempt will be made to obtain expression of a transgene, and if so, the function of the protein that will be produced. The committee assessed key risks presented by the research and confirmed the appropriate biocontainment level for the conduct proposed.

The following action items were identified as needing to be updated on the protocol:

Location of Study

Rooms 37 and 38 should be changed to ABSL2 from BSL2 to reflect the location of animal work.

Risk Assessment

Change the route of lentiviral transmission to mucous membrane and move inhalation to the comments section.

Infectious Agents

The source of the lentiviral vector should be added as well as a reference describing it as replication incompetent.

Vertebrate or Invertebrate Animals

In the table under column “items that can be contaminated,” it states all items listed; this needs clarification.

Exposure Control

ABSL2 PPE should be selected.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

3. IBC Protocol #: 04-10-19-05, Lippi, Giordano

Title of Study: Functional mapping of the neuronal targetome

Department: Neuroscience

Primary Reviewer: Michael Bobardt

Secondary Reviewer: Case McNamara

NIH Guidelines: III-D-1, III-D-2, III-D-4-b, III-D-8

Biosafety Level: BSL-2, ABSL-1

Animal work: ☒ Yes ☐ No

Biosafety Inspection: Inspection of DNC 222, 244, 153, 115, 246 to be completed on 6/5/2025.

Training: Training verified and on record.

Summary of Discussion: A summary of the research proposal was thoroughly discussed, including but not limited to: agent characteristics; types of manipulations planned; sources of the nucleic sequences; nature of the nucleic acid sequences; hosts and vectors to be used; whether any attempt will be made to obtain expression of a transgene, and if so, the function of the protein that will be produced. The committee assessed key risks presented by the research and confirmed the appropriate biocontainment level for the conduct proposed.

The following action items were identified as needing to be updated on the protocol:

General Information

The IACUC (AUP) protocol needs to be attached.

Infectious Agents

Change pseudorabies virus to single cycle infectious rabies virus.

Toxins

The tetrodotoxin SOP and hazard summary needs to be attached here.

Study Design/Project Description

A detailed description of the planned experiments for tetrodotoxin needs to be added here.

Door cards need to be attached here.

Regulatory Assessment

Section III-D-8, “Experiments Involving Gene Drive Modified Organisms” was checked. A detailed description of the vectors and inserts where the gene drive portion of the constructs should be added to the Study Design/Project Description tab.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

4. IBC Protocol #: 09-12-18-02, Lipton, Stuart

Title of Study: Human tissues and cell lines
Department: Molecular & Cellular Biology
Primary Reviewer: Case McNamara
Secondary Reviewer: Roberto Aiolfi
NIH Guidelines: III-D-1, III-D-4-b, III-E-1
Biosafety Level: BSL-2+, ABSL-2
Animal work: ☒ Yes ☐ No
Biosafety Inspection: Inspection of CHWL 153, 156, 152, 164 to be completed 7/2/2025.
Training: Training verified and on record.

Summary of Discussion: A summary of the research proposal was thoroughly discussed, including but not limited to: agent characteristics; types of manipulations planned; sources of the nucleic sequences; nature of the nucleic acid sequences; hosts and vectors to be used; whether any attempt will be made to obtain expression of a transgene, and if so, the function of the protein that will be produced. The committee assessed key risks presented by the research and confirmed the appropriate biocontainment level for the conduct proposed.

The following action items were identified as needing to be updated on the protocol:

Study Design/Project Description

There is mention of use of rats in the described planned experiments description. There is no mention of rats in the vertebrate or invertebrate animals tab or in the containment assessment under the general information tab. This needs resolution.

A detailed description of the planned experiments for tetrodotoxin needs to be added here.

Infectious Agents

Sendai virus is listed as an agent in use, but there is not experimental information about this agent. A description of the use of this agent needs to be added to the Study Design/Project Description tab.

Toxins

The tetrodotoxin SOP and hazard summary needs to be attached here.

DURC-PEPP

Attach the PI assessment form.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

DMR REVIEW

1. IBC Protocol #: 12-09-20-05, Hang, Howard

Title of Study: Immunotherapy Studies
Department: Immunology & Microbiology
NIH Guidelines: III-D-2, III-D-4-b
Biosafety Level: BSL-2, ABSL-2
Animal work: ☒ Yes ☐ No
Training: Training verified and on record.

REVIEW OUTCOME: Pending approval.

2. IBC Protocol #: 06-09-21-05, Voss, James

Title of Study: Studies of long-Term Humoral Protection Against Antibody Resistant Pathogens
Department: Immunology & Microbiology

NIH Guidelines: III-D-1, III-D-2, III-D-3, III-D-4-b, III-D-8
Biosafety Level: BSL-2, ABSL-2
Animal work: ☒ Yes ☐ No
Training: Training verified and on record.
REVIEW OUTCOME: Approved.

BIOSAFETY REVIEW

1. IBC Protocol #: 11-08-23-01, Wyatt, Richard
Title of Study: Wyatt Lab Protocol
Department: Immunology & Microbiology
NIH Guidelines: III-E-1
Biosafety Level: BSL-2+, ABSL-1
Animal work: ☒ Yes ☐ No
Training: Training verified and on record.
REVIEW OUTCOME: Approved.

VI. ADJOURNMENT

The next scheduled IBC meeting is **Wednesday, July 9, 2025**, via Teams at 2:00 PM. If full committee review protocols are not received by the next deadline date and there are no agenda items for full committee discussion, the meeting will be canceled.